Source link : https://www.newshealth.biz/health-news/fda-oks-first-oral-agent-for-eosinophilic-esophagitis/
The US Food and Drug Administration (FDA) has approved budesonide oral suspension (Eohilia, Takeda), the first oral treatment for eosinophilic esophagitis (EoE). Budesonide oral suspension is a corticosteroid indicated for 12 weeks of treatment of EoE in adults and children as young as 11 years. It will be available in 2-mg/10-mL single-dose stick packs by […]
Author : News Health
Publish date : 2024-02-12 20:01:12
Copyright for syndicated content belongs to the linked Source.